Skip to main content

Journal Club

Tumor/Skull Base

Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial

The Lancet Oncology | 2017

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1016/S1470-2045(17)30441-2

PMID

N/A

PICO

Population

Adults from 48 US and Canadian institutions with one resected brain metastasis and a cavity under 5 cm, with up to three small unresected metastases allowed.

Intervention

Postoperative stereotactic radiosurgery to the surgical cavity.

Comparator

Whole brain radiotherapy.

Outcomes

Cognitive-deterioration-free survival, overall survival, six-month cognitive decline, intracranial control, and toxicity.

Design

Type

Multicenter randomized controlled phase 3 trial

Randomized

Yes

Multicenter

Yes

Blinded

Neuropsychologists grading cognitive tests were masked; patients and treating clinicians were not

Follow-up

Median 11.1 months

Primary endpoint

Cognitive-deterioration-free survival and overall survival.

Secondary endpoints

  • Six-month cognitive deterioration
  • Quality of life and functional independence
  • Local and distant intracranial recurrence and leptomeningeal disease

Practice impact

What this means

This phase 3 trial is practice-changing. After resection of a brain metastasis, postoperative cavity SRS preserved cognition better than WBRT and did not worsen overall survival. The short version is simple: if a patient can safely receive cavity SRS, routine WBRT should usually stop being the default.

Bottom line

After resection of a brain metastasis, cavity SRS is a strong option to preserve cognition without sacrificing overall survival, and it should generally be favored over routine WBRT when anatomy and workflow allow it.

Strength of evidence

moderate

Recommendation

change practice

Why it matters

  • This was an adequately powered randomized trial rather than a retrospective series.
  • SRS reduced cognitive decline substantially while overall survival was unchanged.
  • The paper explicitly argues that postoperative SRS should be considered a standard-of-care alternative to WBRT.

What would change my mind

  • A modern randomized comparison showing that hippocampal-sparing WBRT plus current neuroprotection preserves cognition as well as cavity SRS.
  • Robust evidence that local-control failures after SRS produce worse patient-centered outcomes than the cognitive harm avoided by skipping WBRT.

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

Treatment was open-label, which can influence symptom reporting and clinician behavior even though cognitive test grading was masked.

Confounding

Randomization and stratification were strong, but treatment intensity still varied by cavity volume, institutional WBRT fractionation preference, and management of unresected metastases.

Missing data

The six-month cognitive analysis used evaluable subsets rather than all randomized patients, although the protocol counted death or missed early testing as deterioration in the time-to-event endpoint.

Multiplicity

The trial had co-primary endpoints plus many secondary intracranial-control and quality-of-life outcomes, so individual secondary findings need contextual interpretation.

Notes

  • This is the strongest level of evidence in the repair set so far because it is an adequately powered phase 3 randomized trial.
  • The paper directly addresses the common tradeoff between intracranial control and cognitive preservation after resection.

Stats check

NNT

N/A

Effect sizes

  • Cognitive-deterioration-free survival favored SRS (HR 0.47, 95% CI 0.35-0.63; p<0.0001).
  • Overall survival did not differ between groups (HR 1.07, 95% CI 0.76-1.50; p=0.70).

Absolute effects

  • At six months, cognitive deterioration occurred in 28 of 54 evaluable SRS patients (52%) versus 41 of 48 evaluable WBRT patients (85%).
  • Median cognitive-deterioration-free survival was 3.7 months with SRS versus 3.0 months with WBRT.
  • Median overall survival was 12.2 months with SRS versus 11.6 months with WBRT.

Concerns

  • Cognitive outcomes at six months were based on evaluable survivors, which is clinically sensible but still vulnerable to attrition effects.
  • The paper emphasizes cognition and survival, while local-control tradeoffs require the full recurrence analysis.

External validity

Who it applies to

Adults with a resected brain metastasis who are candidates for focused postoperative cavity radiation and want to preserve cognitive function.

Who it does not

Patients with leptomeningeal disease, lesions too close to the optic chiasm or brainstem, or histologies excluded from the trial such as lymphoma or small-cell carcinoma.

Generalizability notes

  • The trial reflects North American and Canadian practice across 48 institutions, which supports broad use in modern oncology settings.
  • Applicability is strongest for patients with limited brain metastatic burden and a resected dominant lesion.
  • Current practice may further evolve with hippocampal-sparing WBRT and memantine, which were not the comparator here.

Evidence trace

Source trace and metadata

Citations (3)

claim_id

methods_critique.risk_of_bias

locator

p. 5

claim_id

stats_check.effect_sizes

locator

p. 3

claim_id

practice_impact.bottom_line

locator

p. 3

quote

SRS radiosurgery should be considered one of the standards of care as a less toxic alternative to WBRT

Metadata

Generated at

2026-03-08T04:15:00Z

Version

manual-pdf-repair-v1